Homocysteine and other cardiovascular risk factors in patients with lichen planus

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 11, 2014, Pages 1507-1513

  Saleh, N ^a   Samir, N ^a   Megahed, H ^b   Farid, E ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LICHEN PLANUS; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 85007275705     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12329     Document Type: Article

References (33)

1. Iijima W, Ohtani H, Nakayama T et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 2003; 163: 261–268.
2. Jonasson T, Ohlin AK, Gottsäter A, Hultberg B, Ohlin H. Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease a prospective randomized study of vitamin supplementation. Clin Chem Lab Med 2005; 43: 628–634.
3. Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM 2003; 96: 711–729.
4. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 2007; 4: 143–150.
5. Hodeib AA, Elsharawy TA, Fawzi HA. Assessment of serum homocysteine, endothelin-1and nitric oxide levels in behçet's disease. Indian J Dermatol 2010; 55: 215–220.
6. Ozkan Y, Yardim-Akaydin S, Imren E, Touran M, Simsek B. Increased plasma homocysteine and allantoin levels in coronary artery disease: possible link between homocysteine and uric acid oxidation. Acta Cardiol 2006; 61: 432–439.
7. Zhu W, Huang X, Li M, Neubauer H. Elevated plasma homocysteine in obese school children with early atherosclerosis. Eur J Pediatr 2006; 165: 326–331.
8. Huang CF, Hsieh MY, Yang JF et al. Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. Hepatol Int 2010; 4: 621–627.
9. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47: 403–411.
10. Romero Corral A, Montori A, Somers VK et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. The Lancet 2006; 368: 666–678.
11. Alberti KG, Eckel RH, Grundy SM et al.”Harmonizing the metabolic syndrome”: a joint interim statement of the international diabetes federation task force on epidemiology and prevention national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009; 120:1640–1645.
12. Arrieta JJ, Rodriguez-Inigo E, Casqueiro M et al. Detection of hepatitis C virus replication by In situ hybridization in epithelial cells of anti-hepatitis C virus positive patients with and without oral lichen planus. Hepatology 2000; 32: 97–103.
13. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278–301.
14. Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology 2007; 58: 513–522.
15. Nasir K, Tsai M, Rosen BD et al. Elevated homocysteine is associated with reduced regional left ventricular function. The Multi-Ethnic Study of Atherosclerosis. Circulation 2007; 115: 180–187.
16. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Medicine 1998; 49: 31–62.
17. Malerba M, Gisondi P, Radaeli A, Sala R. Calzavara Pinton PG and Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155: 1165–1169.
18. Brazzelli V, Grasso V, Fornara L et al. Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity. Int J Immunopathol Pharmacol 2010; 23: 911–916.
19. Gisondi P, Fantuzzi F, Malerba M, Girolomoni G. Folic acid in general medicine and dermatology. J Dermatolog Treat 2007; 18: 138–146.
20. Gisondi P, Malerba M, Malara G et al. C reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol 2010; 23: 1195–1202.
21. Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol 2009; 129: 315–319.
22. Simark-Mattson C, Bergen hottz G, jontell M et al. Distribution of interleukin 2, 4, 10, tumor necrosis factor alpha and transforming growth factor–beta mRNA in oral lichen planus. Arch Oral Biol 1999; 44: 499–507.
23. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and Myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368–1377.
24. Thompson SG, Keinast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and their risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. (ECAT). N Engl J Med 1995; 332: 635–641.
25. Arias-Santiago S, Buendía-Eisman A, Aneiros-Fernández J et al. Cardiovascular Risk Factors in Patients with Lichen Planus. Am J Med 2011; 124: 543–548.
26. Levi M, Nieuwdorp M, van der Poll T, Stroes E. Metabolic modulation of inflammation-induced activation of coagulation. Semin Thromb Hemost 2008; 34: 26–32.
27. Lemieux I, Lamarche B, Couillard C et al. Total cholesterol/HDLcholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001; 161: 2685–2692.
28. Arias-Santiago S, Buendı′a-Eisman A, Aneiros-Ferna′ndez J et al. Lipid levels in patients with lichen planus: a case–control study. Eur Acad Dermatol Venereol 2011; 25: 1398–1401.
29. Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case–control study. Br J Dermatol 2009; 161: 626–629.
30. Agarwal S, Shlipak MG, Kramer H, Jain A, Herrington DM. The association of chronic kidney disease and metabolic syndrome with incident cardiovascular events: multiethnic study of atherosclerosis. Cardiol Res Pract 2012; 2012: 806102.
31. Mehta NN, McGillicuddy FC, Anderson PD et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 2010; 59: 172–181.
32. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone 2007; 8: 11–28.
33. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107: 499–511.